Precision Oncology and Diagnostics

Register Now Click Here

October 19-20, 2023 – Chicago, IL

GenomeWeb and The Precision Medicine Leaders’ Summit present the


as part of our comprehensive coverage of the Precision Medicine Continuum

Join us at the 2022 PMLS Liquid Biopsy Virtual Summit to hear how non-invasive blood-based biomarker testing is changing the practice of oncology. The event will take place on December 6, 2022, from 10:00 am to 3:00 pm EST.

What is the 2022 PMLS Liquid Biopsy Virtual Summit?

Liquid biopsies offer several benefits over traditional tissue-based testing, due to their non-invasive nature and their ability to allow for continuous patient monitoring. From a simple blood draw, tumor-derived entities like circulating tumor cells, circulating tumor DNA, tumor extracellular vesicles, extracellular proteins, and other biomarkers are isolated and analyzed in order to guide treatment or assess prognosis or response to therapy. There are also a number of efforts underway to develop liquid biopsy tests to screen for multiple cancers well before they can be detected with traditional screening approaches.

The underlying technology for liquid biopsies is still evolving, however, and guidance on the clinical implementation of these tests is just beginning to emerge. While the non-invasive nature of the approach promises to drive rapid advances in precision oncology, there are still many unanswered questions regarding the best use of these tests within the context of tissue biopsies and other testing modalities.

The 2022 PMLS Liquid Biopsy Virtual Summit will gather key opinion leaders in the liquid biopsy field to discuss their experiences in implementing these tests in the clinical setting.

Attendees will include oncologists, pathologists, clinical lab managers, executives and decision makers at hospital and health care systems, regulatory leaders in government and business affairs groups, test developers, and more.

Topics to be discussed:

  • Current trends in liquid biopsy testing workflows
  • Advances in isolating circulating tumor cells
  • Regulatory and reimbursement considerations for ctDNA testing
  • MRD testing: opportunities and challenges
  • Liquid versus tissue: when to use each sample type
  • The promise of epigenetic markers for liquid biopsy
  • Liquid biopsy for early cancer detection
  • Applications for cell-free DNA testing beyond oncology